Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
V. Melchionda, H. Wyatt, R. Garcia Medina, A. Solamali, S. Katiri, S. Hopkins, I. Cropley, M. Lipman (London, United Kingdom). Aminoglycoside ototoxicity monitoring in multidrug resistant tuberculosis: How much is enough?. Eur Respir J 2012; 40: Suppl. 56, 4290

Member's Comments

No comment yet.

Related content which might interest you: Amikacin treatment for multidrug resistant tuberculosis: how much monitoring is required? Source: Eur Respir J 2013; 42: 1148-1150 Year: 2013 Monitoring of amikacin-induced ototoxicity during the treatment of multidrug resistant tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002 Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis? Source: Eur Respir J 2016; 48: 582-585 Year: 2016 The surgery of multidrug resistant tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 556s Year: 2003 Treatment possibilities of multi-drug resistant (MDR) tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 525s Year: 2003 Multidrug resistant tuberculosis: clinical aspects and management Source: Eur Respir J 2001; 18: Suppl. 33, 235s Year: 2001 Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Source: Eur Respir J 2008; 31: 904-905 Year: 2008 Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance Source: Eur Respir J, 49 (6) 1700223; 10.1183/13993003.00223-2017 Year: 2017 Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use Source: Eur Respir J, 50 (6) 1701633; 10.1183/13993003.01633-2017 Year: 2017 Multidrug resistant pulmonary TB: Characteristics of drug resistance profiles of MBT in Ukraine Source: Annual Congress 2011 - Epidemiology of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2011 Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis Source: Eur Respir J, 57 (4) 2004454; 10.1183/13993003.04454-2020 Year: 2021 Comparison of moxifloxacin and ofloxacin in treatment of multidrug resistant pulmonary tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Treating multiple-drug resistant tuberculosis Source: International Congress 2018 – PG13 Challenges in the treatment of tuberculosis Year: 2018 Rapid molecular detection of rifampicin and isoniazid resistance and identification of mutations in resistant genes of multi-drug resistant tuberculosis (MDR-TB) patients Source: Annual Congress 2011 - Novel strategies for the diagnosis of tuberculosis Year: 2011 Cost of tuberculosis in the era of multidrug resistance: will it become unaffordable? Source: Eur Respir J 2012; 40: 9-11 Year: 2012 Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB Source: Eur Respir J 2009; 33: 581-585 Year: 2009 Treatment outcome of multi-drug resistant tuberculosis Source: Annual Congress 2004 - Problems of resistance and HIV coinfection in tuberculosis Year: 2004 Outcome of multidrug resistant pulmonary tuberculosis Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010 Reasons for multidrug resistant tuberculosis early relapses Source: Eur Respir J 2002; 20: Suppl. 38, 360s Year: 2002 Safety and efficacy of linezolid, clarithromycin and capreomycin in the treatment of multi-drug resistant pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 587s Year: 2006